Israel's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
PLX•Outlook
- Protalix sees 2026 total revenue of $78 mln to $83 mln, including $25 mln milestone
- Company expects 2026 Elfabrio sales, excluding milestones, of $33 mln to $35 mln
- Protalix expects 2026 Elelyso sales of $20 mln to $23 mln
Overview
- Israel biopharma firm's Q2 revenue from selling goods rose yr/yr, driven by Elfabrio sales
- Q2 net income increased to $3.8 mln from $164,000 a yr earlier
- Company reiterated full-year 2026 revenue guidance of $78 mln to $83 mln
Key details
| Metric | Actual |
|---|---|
| Q2 Revenue | $19.90 mln |
| Q2 EPS | $0.05 |
| Q2 Net Income | $3.78 mln |
| Q2 Operating Income | $4.67 mln |
| Q2 Pretax Profit | $4.86 mln |
The one available analyst rating on the shares is "buy". The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 13 three months ago.
Result drivers
- Elfabrio sales - Co said Q2 revenue growth was driven primarily by continued penetration and growth of Elfabrio, especially through partnership with Chiesi
